Bioventus Inc.·4

Jun 4, 4:46 PM ET

Cowdy Philip G. 4

Research Summary

AI-generated summary

Updated

Bioventus (BVS) Director Philip Cowdy Exercises RSUs, Receives Award

What Happened

  • Philip G. Cowdy, a member of Bioventus Inc.'s board of directors, had 32,282 restricted stock units (RSUs) vest and be converted/exercised into shares on June 2, 2026 (reported as exercise/conversion of a derivative, code M). The filing shows these 32,282 RSUs were acquired at $0.00 (total value reported $0) and a corresponding derivative disposition of 32,282 units at $0.00. On June 3, 2026 he was granted 25,146 RSUs (code A) reported at $0.00 (total value $0).

Key Details

  • Transaction dates and codes: June 2, 2026 — exercise/conversion of derivative (M) for 32,282 RSUs (acquired) and a corresponding derivative disposition for 32,282; June 3, 2026 — grant/award (A) of 25,146 RSUs.
  • Reported price/value: $0.00 per share/unit in the filing (standard for RSU conversions and grants; no cash paid/received shown).
  • Shares owned after the transactions: not specified in the provided filing excerpt.
  • Footnotes: F1 — each RSU equals a contingent right to one share of Class A common stock; F2 — the RSUs that converted vested on June 2, 2026; F3 — the newly granted RSUs vest on the earlier of the first annual meeting after grant or the first anniversary of grant, subject to continued board service.
  • Filing timeliness: Form 4 filed June 4, 2026 for June 2–3 transactions (within the typical two-business-day reporting window).

Context

  • These entries involve RSUs (derivative awards), not open-market purchases or sales. The exercise/conversion at $0 typically reflects RSUs vesting and converting into shares rather than a cash purchase. The June 3 grant is a future-vesting award subject to service-based vesting conditions and does not represent an immediate market purchase or sale.